We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates
multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or …

Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …

BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and
durable responses in multiple myeloma. However, relapse following therapy is frequently …

The lymphocyte genome is prone to many threats, including programmed mutation during
differentiation, antigen-driven proliferation and residency in diverse microenvironments …

All normal somatic cells are thought to acquire mutations, but understanding of the rates,
patterns, causes and consequences of somatic mutations in normal cells is limited. The …

Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Multiple myeloma (MM) is consistently preceded by precursor conditions recognized
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …